Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Monday, down -3.11% from the previous trading day, before settling in for the closing price of $13.82. Over the past 52 weeks, ARQT has traded in a range of $7.86-$17.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -0.98% over the past five years. While this was happening, its average annual earnings per share was recorded 52.80%. With a float of $104.81 million, this company’s outstanding shares have now reached $119.14 million.
Let’s look at the performance matrix of the company that is accounted for 342 employees. In terms of profitability, gross margin is 88.39%, operating margin of -57.0%, and the pretax margin is -60.67%.
Arcutis Biotherapeutics Inc (ARQT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.07%, while institutional ownership is 98.76%. The most recent insider transaction that took place on Jul 01 ’25, was worth 127,430. In this transaction Director of this company sold 9,208 shares at a rate of $13.84, taking the stock ownership to the 100,206 shares. Before that another transaction happened on Jul 01 ’25, when Company’s Director proposed sale 9,208 for $13.84, making the entire transaction worth $127,431.
Arcutis Biotherapeutics Inc (ARQT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 52.80% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 3.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach 0.19 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 1.68 million, a negative change from its year-to-date volume of 2.24 million. As of the previous 9 days, the stock’s Stochastic %D was 25.78%.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 34.14%, which indicates a significant increase from 24.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.49% in the past 14 days, which was lower than the 67.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.99, while its 200-day Moving Average is $12.84. Nevertheless, the first resistance level for the watch stands at $13.78 in the near term. At $14.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.52. If the price goes on to break the first support level at $13.03, it is likely to go to the next support level at $12.67. Assuming the price breaks the second support level, the third support level stands at $12.29.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 1.60 billion has total of 119,202K Shares Outstanding. Its annual sales at the moment are 196,540 K in contrast with the sum of -140,040 K annual income. Company’s last quarter sales were recorded 65,850 K and last quarter income was -25,060 K.
